Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | -158.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.16 | N/A | -158.06% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter and highlighted their commitment to addressing these issues. They remain focused on long-term goals.
Management expressed concern over current operational challenges.
They emphasized a focus on long-term strategies despite short-term setbacks.
The earnings report reflects ongoing challenges for Amicus Therapeutics, particularly with their EPS significantly missing expectations. The stock's 6.51% drop indicates investor concern over the company's current performance and lack of guidance. Without clear direction from management, uncertainty may continue to weigh on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024